DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service

Food and Drug Administration
Silver Spring MD 20993

May 10, 2019

William V. Williams
Contraceptive Study Group
620 South Eagle Road
Havertown, PA 19083

Sent via email to: william.v.williams@verizon.net

Dear Petitioner:

Your *revised* petition to the Food and Drug Administration requesting that the Commissioner remove from the market the injectable contraceptive Depot Medroxyprogesterone Acetate (DMPA; Depo Provera) based on conclusive evidence that it facilitates the transmission of HIV from men to women was received by this office on 05/09/2019.

It was assigned docket number FDA-2019-P-2289. Please refer this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Dynna Gorham-bigby -S

Digitally signed by Dynna Gorham-bigby -S
Date: 2019.05.10 13:15:23 -04'00'

Dynna Bigby
Supervisory Administrative Proceedings Officer
Division of Dockets Management
FDA/Office of Operations (OO)

cc: HeeSun Smaldore
Biologics Conuslting
hsmaldore@biologicsconsulting.com